| (Values in U.S. Thousands) | Jun, 2023 | Mar, 2023 | Sep, 2022 | Jun, 2022 | Mar, 2022 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,181 | -7,654 | -95 | -3,322 | -2,512 |
| Net Income Growth | +58.44% | -7,974.36% | +97.15% | -32.26% | +55.44% |
Mydecine Innovations Group Inc (MYCO.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.
Fiscal Year End Date: 12/31